Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)Depreciation Expense EBIAT Gross Profit Leases Loans and Notes Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

InMed Pharmaceuticals (INM) Long-Term Debt Repayments (2020 - 2023)

InMed Pharmaceuticals has reported Long-Term Debt Repayments over the past 3 years, most recently at $94400.0 for Q4 2023.

For Q4 2023, Long-Term Debt Repayments fell 12.76% year-over-year to $94400.0; the TTM value through Dec 2023 reached $410572.0, up 28.8%, while the annual FY2023 figure was $426575.0, 24.78% up from the prior year.
Long-Term Debt Repayments for Q4 2023 was $94400.0 at InMed Pharmaceuticals, down from $98709.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $214791.0 in Q4 2021 and troughed at $17411.0 in Q3 2021.
A 3-year average of $96154.6 and a median of $99806.0 in 2022 define the central range for Long-Term Debt Repayments.
On a YoY basis, Long-Term Debt Repayments climbed as much as 479.54% in 2022 and fell as far as 49.62% in 2022.
Year by year, Long-Term Debt Repayments stood at $214791.0 in 2021, then tumbled by 49.62% to $108209.0 in 2022, then dropped by 12.76% to $94400.0 in 2023.
Business Quant data shows Long-Term Debt Repayments for INM at $94400.0 in Q4 2023, $98709.0 in Q3 2023, and $109085.0 in Q2 2023.